# Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

> **NCT04195828** · PHASE2 · COMPLETED · sponsor: **Fujian Medical University** · enrollment: 106 (actual)

## Conditions studied

- Advanced Gastric Cancer

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Apatinib Mesylate
- **DRUG:** nab-paclitaxel
- **DRUG:** S1

## Key facts

- **NCT ID:** NCT04195828
- **Lead sponsor:** Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-18
- **Primary completion:** 2022-07-22
- **Final completion:** 2025-03-24
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2025-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04195828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04195828, "Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04195828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*